Ifyltan (Fentanyl)

• Ifyltan (fentanyl) acts on the mu‑opioid receptor pathway to provide potent analgesia for severe pain conditions.
• Severe pain: delivers strong, continuous relief for patients with intense acute or chronic pain.
• Cancer pain: controls malignant disease‑related pain that is unresponsive to weaker opioids.
• Breakthrough cancer pain: provides rapid relief for episodic spikes in pain despite baseline opioid therapy.

• Fentanyl binds selectively to mu‑opioid receptors in the central nervous system, activating inhibitory G‑protein pathways that reduce neuronal excitability and suppress the release of pain‑transmitting neurotransmitters such as substance P and glutamate, resulting in potent analgesic effects.

Fentanyl may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Nausea and vomiting
• Constipation
• Drowsiness or sedation
• Dizziness or light‑headedness
• Dry mouth
• Sweating

Serious or Rare Side Effects

• Respiratory depression, which can be life‑threatening
• Severe hypotension or cardiovascular collapse
• Chest wall rigidity
• Development of physical dependence or addiction
• Overdose leading to coma or death
• Adrenal insufficiency

When prescribing or dispensing Ifyltan, several safety considerations should be observed.

• Assess respiratory function: ensure adequate ventilation before initiating therapy.
• Evaluate opioid tolerance: confirm the patient is opioid‑experienced to reduce overdose risk.
• Monitor for signs of dependence: watch for cravings, withdrawal, or misuse behaviors.
• Avoid use in severe asthma or uncontrolled respiratory disease.
• Adjust dose in hepatic impairment: reduced clearance may increase plasma levels.
• Store at ambient temperature: keep in the original packaging, protect from moisture and light.

Fentanyl can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Concomitant central nervous system depressants (e.g., benzodiazepines, barbiturates) may cause profound respiratory depression.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) can increase fentanyl plasma concentrations.

Moderate Interactions (Monitor Closely):\n- Moderate CYP3A4 inhibitors (e.g., erythromycin) may modestly raise fentanyl levels.

• CNS stimulants (e.g., tramadol) can increase seizure risk.
• MAO inhibitors: concurrent use may precipitate hypertensive crises or serotonin syndrome.